European Archives - Page 1133 of 1159 - European Medical Journal

Can Primary Care Physicians Manage Benign Prostatic Hyperplasia Patients As Urologists Do?

Most clinical practice guidelines (CPGs) assume that general practitioners (GPs) can manage non- complicated benign prostatic hyperplasia (BPH)-related…

A Very Rare Entity of Benign Prostatic Inflammation: Xanthogranulomatous Prostatitis

Prostatitis is a commonly seen clinical entity in daily urological practice.

EMJ

Advancements and Updates in the Field of Enuresis

Summary of the Enuresis Lecture, held at the 25th Annual ESPU Congress, Innsbruck, Austria, on 9th May 2014

EMJ

EMJ Urology 1 [Suppl 1] 2014

Dr Austin’s presentation aimed to provide a state-of-the-art review on enuresis, focusing on diagnosis, treatment strategies, and management of…

EMJ

Update: Diagnosis and Treatment of Muscle-Invasive and Metastatic Bladder Cancer in 2014

Bladder cancer (BC) is the ninth most commonly diagnosed malignant tumour in the world, with an incidence of about 356,000 and a mortality of about 145,000 per year in both non-muscle-invasive and muscle-invasive BC.

Percutaneous Nephrolithotomy in Children

Although urolithiasis is considered as a rare entity in children, it is an important health problem in the world, especially in endemic areas.

Biosimilars in Hematology: Increasing Choice, Expanding Access

Biologicals have revolutionised modern medicine by offering vital therapeutic options to treat or prevent complex, disabling, and life-threatening diseases.

Next Steps in Front-Line Treatment of Lymphoma: The Road Ahead

Prof Zelenetz opened the symposium on the evolving front-line treatment options for follicular lymphoma (FL) and discussed the potential of novel agents…

The Multiple Facets of Thrombotic Microangiopathies

The Alexion satellite symposium was introduced by Prof Pier Mannuccio Mannucci who provided an introduction to the history of thrombotic…

The Standard of Care in Relapsed Refractory CD30+ Lymphoma

CD30-positive (CD30+) lymphomas are a heterogeneous group of hematological malignancies that share the same antigen. Over recent decades, advances…